Soleus Capital Management L.P. Invests $15.47 Million in Septerna, Inc. (NASDAQ:SEPN)

Soleus Capital Management L.P. acquired a new stake in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 675,409 shares of the company's stock, valued at approximately $15,467,000. Soleus Capital Management L.P. owned about 1.52% of Septerna as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in Septerna during the fourth quarter worth about $871,000. MetLife Investment Management LLC purchased a new stake in Septerna in the 4th quarter worth approximately $265,000. Barclays PLC acquired a new stake in shares of Septerna during the 4th quarter worth approximately $659,000. TRV GP VI LLC acquired a new stake in shares of Septerna during the 4th quarter worth approximately $72,191,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Septerna during the 4th quarter valued at approximately $506,000.

Insider Buying and Selling at Septerna

In other Septerna news, CFO Gil M. Labrucherie bought 6,282 shares of Septerna stock in a transaction dated Tuesday, February 25th. The stock was acquired at an average cost of $5.59 per share, for a total transaction of $35,116.38. Following the completion of the transaction, the chief financial officer now directly owns 36,282 shares of the company's stock, valued at approximately $202,816.38. This represents a 20.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alan Ezekowitz purchased 41,355 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the transaction, the director now directly owns 104,101 shares of the company's stock, valued at $624,606. The trade was a 65.91% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 63,846 shares of company stock worth $381,815. Corporate insiders own 4.30% of the company's stock.

Septerna Trading Up 4.6%

SEPN stock traded up $0.42 during trading on Thursday, hitting $9.48. The stock had a trading volume of 700,380 shares, compared to its average volume of 717,031. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99. The company's 50-day moving average price is $6.61 and its two-hundred day moving average price is $14.02.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The firm had revenue of $0.22 million during the quarter. On average, sell-side analysts anticipate that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on SEPN shares. Cantor Fitzgerald increased their price target on shares of Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Wells Fargo & Company upped their price objective on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.